FDA omidubicel-onlv coverage for business development, investment, and market access teams
The FDA has approved Omisirge, an innovative allogeneic stem cell therapy designed to treat hematologic cancers, marking a significant advancement in cancer care.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
